Performance medicine is emerging as a field dedicated to optimizing human physical and cognitive capabilities, extending healthspan, and enhancing recovery, rather than merely treating disease. At its forefront are gene therapy and regenerative medicine, which target the molecular roots of decline, injury, and aging. These approaches promise durable, sometimes one-time interventions that could redefine athletic performance, longevity, and daily vitality. Complementary supplements play a supportive role by aiding cellular repair and optimizing the body's response to these advanced therapies. As of 2026, the sector is accelerating with FDA approvals, clinical milestones, and pioneering companies bridging therapeutic and enhancement applications.

Emerging research in gene therapy highlights precise genetic interventions using adeno-associated virus (AAV) vectors, CRISPR-Cas9 editing, and lentiviral delivery. A landmark example is CRISPR-based editing of hematopoietic stem cells for sickle cell disease, validated by the 2023 FDA approval of Lyfgenia (lovotibeglogene autotemcel), which modifies patient cells to produce functional hemoglobin and reduce vaso-occlusive events. In 2025, approvals expanded with Zevaskyn (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa, marking the first gene-corrected skin therapy, and Waskyra (etuvetidigene autotemcel) for Wiskott-Aldrich syndrome—the first nonprofit-developed lentiviral gene therapy. Ocular and cardiac applications are advancing rapidly: Neurotech’s Encelto received approval for macular telangiectasia type 2, while trials explore AAV therapies for cardiomyocyte regeneration in heart failure.

Regenerative medicine integrates these tools with stem cells, particularly induced pluripotent stem cells (iPSCs). CRISPR engineering creates hypo-immunogenic iPSC lines by knocking out immune-recognition genes, enabling off-the-shelf allogeneic therapies without immunosuppression. In 2025, three iPSC-based therapies gained FDA IND clearance for Parkinson’s disease, spinal cord injury, and ALS. MSC therapies also progressed: Ryoncil (remestemcel-L) was approved in late 2024 for pediatric steroid-refractory acute graft-versus-host disease. Preclinical work shows promise in in vivo reprogramming and exosome delivery for tissue repair. For performance contexts, research targets muscle regeneration and anti-aging hallmarks. Follistatin gene therapy inhibits myostatin to promote muscle growth and reduce fat. Klotho upregulation supports cognition and kidney health, while telomerase (TERT) delivery lengthens telomeres to combat cellular senescence.

Companies are testing these in longevity and performance settings, often outside traditional U.S. regulatory pathways. Minicircle offers non-viral Follistatin (FST-344) gene therapy, administered at international clinics, claiming increases in lean mass, reductions in body fat, and improved recovery with no permanent genomic changes or downtime. Klotho therapy is slated for 2026. BioViva has pursued similar vectors: CEO Liz Parrish received TERT therapy, reporting telomere lengthening equivalent to reversing biological age by about 5 years annually in early data; follistatin increased thigh muscle mass despite reduced exercise; and klotho showed cognitive gains in small cohorts. These “set-it-and-forget-it” approaches align with performance medicine by enhancing strength, endurance, and resilience, though large-scale trials are ongoing and results remain investigational.

Supplements serve as practical adjuncts in regenerative and performance protocols. While not substitutes for gene or cell therapies, targeted nutrients support stem cell proliferation, differentiation, and post-treatment healing. Vitamin C promotes collagen synthesis and connective-tissue repair; zinc accelerates wound healing and tissue regeneration; vitamin D3 modulates immune responses and stem cell function; and B-complex vitamins aid energy metabolism in regenerating cells. Glucosamine sulfate and omega-3s reduce inflammation, creating an optimal environment for MSC or gene-edited cell integration. In lab settings, factors like FGF-2, PDGF-BB, and ascorbic acid have dramatically boosted MSC expansion while preserving differentiation potential. For patients, these supplements enhance recovery after PRP, stem cell injections, or gene therapies by mitigating oxidative stress and supporting epigenetic stability—key for sustained performance gains.

Several organizations drive progress. The Alliance for Regenerative Medicine (ARM) tracks the global pipeline, funding trends, and policy, representing over 400 members and publishing quarterly sector snapshots. The American Society of Gene & Cell Therapy (ASGCT) fosters research, education, and advocacy, awarding millions in grants and hosting annual meetings. The International Society for Cell & Gene Therapy (ISCT) emphasizes translational standards and global collaboration. Commercial leaders include CRISPR Therapeutics and Vertex (sickle-cell pioneers), Sarepta (Duchenne gene therapy), Abeona (Zevaskyn), and biohacking-focused entities like Minicircle and BioViva. CDMO partners such as Minaris Advanced Therapies enable scalable manufacturing.

The importance of this field cannot be overstated. Traditional medicine treats symptoms; gene and regenerative therapies address root causes, potentially curing monogenic diseases, repairing injuries faster, and extending functional lifespan. In performance medicine, they could enable athletes and aging individuals to maintain peak muscle mass, cognitive sharpness, and metabolic health with minimal intervention—reducing injury downtime and healthcare burdens. By 2030, analysts project 54–74 approved cell and gene therapies, treating hundreds of thousands annually and generating tens of billions in value. Supplements democratize access, offering low-cost optimization for everyday users. Yet challenges remain: high costs (some therapies exceed $4 million), manufacturing complexity, equitable access, and ethical questions around enhancement versus therapy. Offshore clinics highlight regulatory gaps, while FDA expedited pathways like RMAT designation accelerate safe innovation.

Looking ahead, integration of AI-driven CRISPR, in vivo reprogramming (as pursued by Altos Labs), and nutrigenomic supplements could personalize performance medicine. A single gene therapy might combine with daily vitamin regimens to sustain gains in strength, recovery, and longevity. As 2025 predictions materialized—with multiple approvals and iPSC advances—the trajectory points to a future where performance is engineered at the genetic level, supported by nutrition, and accessible beyond elite circles. This convergence promises not just longer life, but vastly improved quality and capability for humanity.

Join WoS Now

- A Member Publication of M/s WorldWide Media Corporation Group